Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000006
Chunk: 1

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 1
---
 –
Takeda (TSE:4502/NYSE:TAK) announced that its Board of Directors resolved today to engage in the acquisition of its own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act of Japan, as detailed below.

#### 1.

#### Reason for acquisition of its own shares
To enhance capital efficiency and improve shareholder returns.

#### 2.

#### Details of acquisition
(1) Class of shares to be acquired: Shares of common stock

(2) Number of shares to be acquired: Up to 28.5 million shares

(equivalent to 1.80% of the total number of shares

outstanding excluding treasury shares)

(3) Total amount of shares to be acquired: Up to JPY 100 billion

(4) Schedule of acquisition: From February 17, 2025 to May 31, 2025

(5) Method of acquisition: Open-market repurchase through a trust bank

(Reference)

Treasury shares held by Takeda as of December 31, 2024

Aggregate number of issued shares (excluding treasury shares) 1,585,179,249 shares

Number of treasury shares 5,758,360 shares

#### About Takeda Pharmaceutical Company Limited
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

#### Contacts
| Investor Relations             
 Christopher O’Reilly           
 christopher.oreilly@takeda.com 
 +81 (0) 3-3278-2543            |     | Media Relations                
 Brendan Jennings               
 brendan.jennings@takeda.com    
 +81 (0) 80-2705-8259           
 (Outside Japan business hours) 
 Media_relations